GlassScriptPhysician profile
Nikki Hill
NPI 1447568506
$4,268.02
in general payments reported to CMS, 2019-2025
23 companies · $753 in 2025
The $753 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $110 · 2021: $182 · 2022: $707 · 2023: $1,153 · 2024: $990 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.93 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.17 | 2019-2025 | Dupixent |
| Pfizer INC. | $280.70 | 2019-2024 | |
| Janssen Biotech, INC. | $261.40 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $257.14 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $243.35 | 2022-2024 | |
| Merz North America, INC. | $200.05 | 2023-2025 | Xeomin |
| Arcutis Biotherapeutics, INC. | $193.87 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $187.25 | 2019-2024 | |
| Galderma Laboratories, L.P. | $185.22 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Revance Therapeutics, INC. | $184.98 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $132.63 | 2023-2024 | Sotyktu |
| Incyte Corporation | $113.09 | 2021-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $86.09 | 2022-2023 | |
| Amgen INC. | $74.07 | 2022-2023 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $59.31 | 2022-2024 | |
| Organon LLC | $58.71 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $56.68 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.87 | 2020-2025 | Cabtreo, Jublia, Siliq |
| Leo Pharma INC. | $39.11 | 2022-2025 | Spevigo |
| Botanix Sb INC | $21.04 | 2025 | Sofdra |
| Acelrx Pharmaceuticals, INC. | $11.85 | 2021 | |
| Dermira, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.